USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MODULATION THERAPEUTICS, INC.
Address:
3802 Spectrum Boulevard, Suite 124
Tampa, FL 33612-9220
EIN:
45-268021
DUNS:
968675244
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $663,320.00 3

Award List:

Chemical Optimization Designed to Increase the in vivo Efficacy of HM-27 for the

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$156,202.00
Agency:
HHS
Principal Investigator:
Priyesh Jain – 813-453-8993
Abstract:
DESCRIPTION (provided by applicant): This application requests funds to aid in obtaining the necessary additional preclinical data needed for commercialization of a promising new and novel drug candidate for the treatment of multiple myeloma. A small business, Modulation Therapeutics Incorporated,… More

Targeting CD44 in the bone marrow microenvironment of MM

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$218,817.00
Agency:
HHS
Principal Investigator:
Rajesh R. Nair – 813-453-8993
Abstract:
DESCRIPTION (provided by applicant): The majority of multiple myeloma (MM) patients will initially respond to standard chemotherapy. However, eventually relapse of the disease, associated with a multi-drug resistant phenotype, contributes to poor clinicaloutcomes. Our laboratory has recently… More

A Virtually Supervised Web-Based Home Exercise Technology for Older Adults

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$288,301.00
Agency:
HHS
Principal Investigator:
Lori Hazlehurst – 813-335-7401
Abstract:
DESCRIPTION (provided by applicant): The majority of multiple myeloma (MM) patients will initially respond to standard chemotherapy. However, eventually relapse of the disease, associated with a multi-drug resistant phenotype, contributes to poor clinicaloutcomes. Modulation Therapeutics is… More